Global Ischemic Heart Disease (IHD) Drugs Market

According to the latest report by IMARC Group, titled “Ischemic Heart Disease (IHD) Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027”, the global Ischemic Heart Disease (IHD) drugs market reached a value of US$ 5.8 Billion in 2021. Ischemic heart disease, also known as coronary heart (CHD) or coronary artery disease, refers to a heart problem in which the blood flow to the heart is restricted or reduced. This is caused by clogged arteries that supply less blood and oxygen to the heart muscles, eventually leading to a cardiac attack. The diverse pharmacological actions of various IHD drugs, such as calcium channel blockers, inhibit the influx of calcium ions into the myocardium and vascular smooth muscle tissues. The relaxation of the coronary artery due to calcium channel blocker therapy improves coronary blood flow, thereby increasing myocardial oxygen supply. The anti-ischemic effects of these drugs are often notable, especially the newer agents like amlodipine.

We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of the associated industries. These observations will be integrated into the report.

Global IHD Drugs Market Trends:

In recent years, the increasing prevalence of heart diseases, along with the growing population of older adults who are more prone to heart ailments, has led to the rising demand for IHD drugs. Moreover, IHD drugs are incorporated in various cardiological treatment procedures, such as angioplasty, atherectomy and balloon angioplasty, for preventing relapse and ensuring healthy recovery, which has led to a consistent requirement for these drugs. Besides this, the high alcohol consumption, excessive smoking, reduced blood pressure control and lower physical activity are the factors that have increased the mortality rate from cardiovascular disease, which in turn is leading to a rise in the demand for IHD drugs across the globe. Moreover, several pharmaceutical companies are investing in the development of more advanced IHD drugs. Looking forward, the market is projected to expand at a CAGR of 4.57% during 2022-2027.

Market Summary:

• Based on the disease class, the market has been bifurcated into angina pectoris and myocardial infarction.
• On the basis of the drug class, the market has been segregated into anti-dyslipidemic drugs, calcium channel blockers, beta-blockers, Angiotensin-converting enzyme (ACE) inhibitors, Angiotensin II receptor blockers (ARBs), vasodilators and antithrombotic agents.
• Region-wise, the market has been divided into North America, Asia Pacific, Europe, Middle East and Africa, and Latin America.
• The competitive landscape of the market has also been examined, with some of the key players being Bayer AG, Eli Lilly and Company, Novartis International AG, Pfizer, Inc., Sanofi S.A., Actelion Pharmaceuticals Ltd., Baxter International Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Amgen Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Merck & Co., and Eisai Co., Ltd.

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

IMARC Group
Email: sales@imarcgroup.com
Phone No: (D) +91 120 433 0800 | www.imarcgroup.com 
Americas :- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331